Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

105.55 -0.69 (-0.65%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Cramer Shares His Thoughts On Incyte, Corning And More ↗

December 22, 2021

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Incyte Corporation (NASDAQ:

Via Benzinga

4 Stocks Insiders Are Buying ↗

December 20, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...

Via Benzinga

Incyte's Topical JAK Inhibitor Under Priority FDA Review For Depigmented Skin Disorder ↗

December 15, 2021

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) supplemental marketing application seeking approval for ruxolitinib cream 1.5% (Opzelura), a...

Via Benzinga

Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura™) as a Treatment for Patients with Vitiligo

December 14, 2021

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conferences

December 14, 2021

From Incyte

Via Business Wire

Expert Ratings For Incyte ↗

November 19, 2021

Over the past 3 months, 6 analysts have published their opinion on Incyte (NASDAQ:

Via Benzinga

Why Are Datadog, Zscaler, Airbnb, Fortinet, Lucid Trading Higher Premarket? ↗

December 13, 2021

Airbnb, Inc (NASDAQ: ABNB), Fortinet, Inc (NASDAQ: FTNT), Palo Alto Networks, Inc (NASDAQ: PANW), Lucid Group, Inc (NASDAQ: LCID), Zscaler, Inc (NASDAQ: ZS), and Datadog, Inc (...

Via Benzinga

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

December 11, 2021

From Incyte

Via Business Wire

Annual Changes To The Nasdaq-100 Index ↗

December 11, 2021

The reconstituted Nasdaq index for 2022 (effective Dec. 20, 2021) has six new members; they replace FOX, TCOM, INCY, CDW, CERN, and CHKP.

Via Talk Markets

Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

December 11, 2021

From Incyte

Via Business Wire

7 CEOs That Ought to Follow Jack Dorsey Out the Door ↗

December 10, 2021

Jack Dorsey stepped down as Twitter CEO despite stock gains, but not every CEO can say the same. Here are seven CEOs who need to go.

Via InvestorPlace

Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks

December 08, 2021

FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit...

Via FinancialNewsMedia

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

7 Stocks 'On Sale' This Holiday Season ↗

November 26, 2021

This time of year, it may feel like you’ve missed out on big rallies in the best stocks. But, there may still be a chance to buy some high-quality stocks for 2022 at a discount to what you would have...

Via Talk Markets

7 Stocks 'On Sale' This Holiday Season ↗

November 26, 2021

The SPDR S&P 500 ETF Trust (NYSE: SPY) has generated a total return of 26.4% year-to-date, but much of those overall gains have been driven by a handful of megacap stocks. In...

Via Benzinga

Topics Stocks

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗

November 18, 2021

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...

Via Benzinga

Stocks Most Impacted by 7-10 Year Treasuries ↗

November 17, 2021

A look at S&P 500 members that perform best when the iShares 7-10 Year Treasury Bonds ETF (IEF) loses value.

Via Talk Markets

Topics Stocks

Incyte to Present at Upcoming Investor Conference

November 09, 2021

From Incyte

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition

November 04, 2021

From Incyte

Via Business Wire

Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript ↗

November 02, 2021

INCY earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗

November 02, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares...

Via Benzinga

Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

November 02, 2021

From Incyte

Via Business Wire

A Peek Into The Markets: US Stock Futures Edge Lower; Fed Meeting In Focus ↗

November 02, 2021

Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade after settling at record highs in the previous session. The Federal Open Market Committee will...

Via Benzinga

Topics Economy

Incyte's Parsaclisib Application Under FDA Review For 3 Types Of Non-Hodgkin Lymphomas ↗

November 01, 2021

The FDA has accepted for review Incyte Corporation's (NASDAQ: INCY) marketing application for parsaclisib for relapsed or refractory follicular lymphoma (FL),...

Via Benzinga

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

November 01, 2021

From Incyte

Via Business Wire

Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas

November 01, 2021

From Incyte

Via Business Wire

Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo

October 28, 2021

From Incyte

Via Business Wire

2 Beaten-Down Biotech Stocks That Could Be Great Long-Term Plays ↗

October 27, 2021

It's much too early to count these companies out.

Via The Motley Fool

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

< Previous 1 2

...

18 19 20 21 22 23 24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Incyte Corporation - Common Stock (NQ:INCY)

All News about Incyte Corporation - Common Stock

Starting at $3.75/week.

Subscribe Today